Toxoplasmosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019 On 30th December 2014
Summary The industry analysis specialist, has released its new report, “Toxoplasmosis Therapeutics Pipeline Assessment and Market Forecasts to 2019�. The report is an essential source of information and analysis on the global Toxoplasmosis Therapeutics market. The report identifies the key trends shaping and driving the global Toxoplasmosis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Toxoplasmosis Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
You can buy this Report @ http://www.jsbmarketresearch.com/healthcare-medical/rtoxoplasmosis-therapeutics-pipeline-assessment-and-market-forecasts-135206
Scope
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
The report provides information on the key drivers and challenges of the Toxoplasmosis Therapeutics market. Its scope includes - Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Toxoplasmosis Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019. - Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes. - Analysis of the current and future competition in the seven key countries Toxoplasmosis Therapeutics market. - Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. - Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Toxoplasmosis Therapeutics market. - Analysis of key recent licensing and partnership agreements in Toxoplasmosis Therapeutics market
Reasons to buy The report will enhance your decision making capability. It will allow you to - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. - Develop business strategies by understanding the trends shaping and driving the global Toxoplasmosis Therapeutics market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Toxoplasmosis Therapeutics market in future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. - What’s the next big thing in the global Toxoplasmosis Therapeutics market landscape? – Identify, understand and capitalize.
Other industries we cover: • • • • • • • • •
Advertising and Media Automotive and Parts Consumer Goods Healthcare and Medical Finance and Banking Food and Beverages Travel and Tourism Textiles and Clothing SWOT Analysis
Discounts on Market Research Reports till 31st December, 2014 For more inquiries, contact at +91 - 998 729 5242 / contact@jsbmarketresearch.com Table of Content 2 Toxoplasmosis Therapeutics - Introduction 2.1 Disease Overview 2.1.1 Types of Toxoplasma gondii Strain 2.1.2 Life Cycle and Transmission 2.2 Epidemiology 2.2.1 Historic Epidemiology (2006–2011) 2.2.2 Forecast Epidemiology (2011–2019) Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
2.3 Etiology 2.3.1 Food-borne Transmission 2.3.2 Congenital Transmission 2.3.3 Zoonotic Transmission 2.3.4 Rare Instances of Transmission 2.4 Pathophysiology 2.5 Signs and Symptoms 2.6 Commonly Used Diagnostic Tests 2.6.1 Types of Diagnostic Test 2.7 Treatment and Management Options for Toxoplasmosis 2.7.1 Management of Toxoplasmosis Infection during Gestation 2.7.2 Congenital Toxoplasmosis 2.7.3 Ocular Toxoplasmosis 2.7.4 Toxoplasmosis in Immunocompetent Patients 2.8 GlobalData Pipeline Report Guidance 3 Toxoplasmosis Therapeutics - Market Characterization 3.1 Toxoplasmosis Therapeutics Market Size (2006–2011) – Global 3.2 Toxoplasmosis Therapeutics Market Forecast (2011–2019) – Global 3.3 Toxoplasmosis Therapeutics Market Size (2006–2011) – The US 3.4 Toxoplasmosis Therapeutics Market Forecast (2011–2019) – The US 3.5 Toxoplasmosis Therapeutics Market Size (2006–2011) – France 3.6 Toxoplasmosis Therapeutics Market Forecast (2011–2019) – France 3.7 Toxoplasmosis Therapeutics Market Size (2006–2011) – Germany 3.8 Toxoplasmosis Therapeutics Market Forecast (2011–2019) – Germany 3.9 Toxoplasmosis Therapeutics Market Size (2006–2011) – Italy 3.10 Toxoplasmosis Therapeutics Market Forecast (2011–2019) – Italy 3.11 Toxoplasmosis Therapeutics Market Size (2006–2011) – Spain 3.12 Toxoplasmosis Therapeutics Market Forecast (2011–2019) – Spain 3.13 Toxoplasmosis Therapeutics Market Size (2006–2011) – The UK 3.14 Toxoplasmosis Therapeutics Market Forecast (2011–2019) – The UK 3.15 Toxoplasmosis Therapeutics Market Size (2006–2011) – Japan 3.16 Toxoplasmosis Therapeutics Market Forecast (2011–2019) – Japan 3.17 Drivers and Barriers for the Toxoplasmosis Therapeutics Market 3.17.1 Drivers for the Toxoplasmosis Therapeutics Market 3.17.2 Barriers for the Toxoplasmosis Therapeutics Market 3.18 Opportunity and Unmet Need Analysis Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
3.19 Key Takeaway 4 Toxoplasmosis Therapeutics - Competitive Assessment 4.1 Overview 4.2 Strategic Competitor Assessment 4.3 Product Profiles of the Marketed Products in the Toxoplasmosis Therapeutics Market 4.3.1 Daraprim (pyrimethamine) 4.3.2 Spiramycin 4.3.3 Sulfadiazine 4.3.4 Folinic Acid 4.4 Key Takeaway 5 Toxoplasmosis Therapeutics - Pipeline Assessment 5.1 Overview 5.2 Strategic Pipeline Assessment 5.2.1 Toxoplasmosis Therapeutics – Phase III Clinical Pipeline 5.3 Key Takeaway 6 Toxoplasmosis Therapeutics - Clinical Trial Mapping 6.1 Clinical Trials by Region and Country 6.2 Clinical Trials by Phase 6.3 Clinical Trials by Trial Status 6.4 Clinical Trial Mapping by Sponsors 6.5 Prominent Sponsors 6.6 Companies Participating in Toxoplasmosis Therapeutics Clinical Trials 7 Toxoplasmosis Therapeutics - Strategic Assessment 7.1 Key Events Impacting the Future Market 7.2 Toxoplasmosis Therapeutics: Implications for Future Market Competition 8 Toxoplasmosis Therapeutics Market - Licensing and Partnership Deals 9 Toxoplasmosis Therapeutics Market - KOL Insights, 2012 10 Toxoplasmosis Therapeutics - Appendix 10.1 Market Definitions 10.2 Acronyms 10.3 Bibliography 10.4 Research Methodology 10.4.1 Coverage 10.4.2 Secondary Research 10.4.3 Forecasting 10.4.4 Primary Research Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
10.4.5 Expert Panel Validation 10.5 Contact Us 10.6 Disclaimerr List Of Tables Table 1: Toxoplasmosis Therapeutics Market, Global, Prevalence, 2006-2011 Table 2: Toxoplasmosis Therapeutics Market, Global, Prevalence, 2011-2019 Table 3: Alternative Antibiotics Used in Ocular Toxoplasmosis Table 4: Toxoplasmosis Therapeutics Market, Global, Revenue ($m), 2006-2011 Table 5: Toxoplasmosis Therapeutics Market, Global, Forecast ($m), 2011-2019 Table 6: Toxoplasmosis Therapeutics Market, The US, Revenue ($m), 2006-2011 Table 7: Toxoplasmosis Therapeutics Market, The US, Forecast ($m), 2011-2019 Table 8: Toxoplasmosis Therapeutics Market, France, Revenue ($m), 2006-2011 Table 9: Toxoplasmosis Therapeutics Market, France, Forecast ($m), 2011-2019 Table 10: Toxoplasmosis Therapeutics Market, Germany, Revenue ($m), 2006-2011 Table 11: Toxoplasmosis Therapeutics Market, Germany, Forecast ($m), 2011-2019 Table 12: Toxoplasmosis Therapeutics Market, Italy, Revenue ($m), 2006-2011 Table 13: Toxoplasmosis Therapeutics Market, Italy, Forecast ($m), 2011-2019 Table 14: Toxoplasmosis Therapeutics Market, Spain, Revenue ($m), 2006-2011 Table 15: Toxoplasmosis Therapeutics Market, Spain, Forecast ($m), 2011-2019 Table 16: Toxoplasmosis Therapeutics Market, The UK, Revenue ($m), 2006-2011 Table 17: Toxoplasmosis Therapeutics Market, The UK, Forecast ($m), 2011-2019 Table 18: Toxoplasmosis Therapeutics Market, Japan, Revenue ($m), 2006-2011 Table 19: Toxoplasmosis Therapeutics Market, Japan, Forecast ($m), 2011-2019 Table 20: Toxoplasmosis Therapeutics-Phase III Pipeline, 2012 Table 21: Toxoplasmosis Therapeutics - Clinical Trials by Country, 2012 Table 22: Toxoplasmosis Therapeutics - Clinical Trials by Phase, 2012 Table 23: Toxoplasmosis Therapeutics - Clinical Trials by Status, 2012 Table 24: Toxoplasmosis Therapeutics - Overall Sponsors, 2012 Table 25: Toxoplasmosis Therapeutics - Prominent Sponsors, 2012 Table 26: Toxoplasmosis Therapeutics - Company Participating in Therapeutics Clinical Trials, 2012 Table 27: Toxoplasmosis-Global, Deals, 2012 Table 28: Toxoplasmosis Therapeutics Market, Global, KOL Insights, 2012 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
List Of Figures Figure 1: Diagnosis Algorithm for Congenital Toxoplasmosis Figure 2: Approaches for the Treatment of Pregnant Women Figure 3: Toxoplasmosis Therapeutics Market, Global, Revenue ($m), 2006-2011 Figure 4: Toxoplasmosis Therapeutics Market, Global, Forecast ($m), 2011–2019 Figure 5: Toxoplasmosis Therapeutics Market, The US, Forecast ($m), 2006–2011 Figure 6: Toxoplasmosis Therapeutics Market, The US, Forecast ($m), 2011–2019 Figure 7: Toxoplasmosis Therapeutics Market, France, Revenue ($m), 2006–2011 Figure 8: Toxoplasmosis Therapeutics Market, France, Forecast ($m), 2011–2019 Figure 9: Toxoplasmosis Therapeutics Market, Germany, Revenue ($m), 2006–2011 Figure 10: Toxoplasmosis Therapeutics Market, Germany, Forecast ($m), 2011–2019 Figure 11: Toxoplasmosis Therapeutics Market, Italy, Revenue ($m), 2006–2011 Figure 12: Toxoplasmosis Therapeutics Market, Italy, Forecast ($m), 2011–2019 Figure 13: Toxoplasmosis Therapeutics Market, Spain, Revenue ($m), 2006–2011 Figure 14: Toxoplasmosis Therapeutics Market, Spain, Forecast ($m), 2011–2019 Figure 15: Toxoplasmosis Therapeutics Market, The UK, Revenue ($m), 2006–2011 Figure 16: Toxoplasmosis Therapeutics Market, The UK, Forecast ($m), 2011–2019 Figure 17: Toxoplasmosis Therapeutics Market, Japan, Revenue ($m), 2006–2011 Figure 18: Toxoplasmosis Therapeutics Market, Japan, Forecast ($m), 2011–2019 Figure 19: Opportunity and Unmet Need in the Toxoplasmosis Therapeutics Market Figure 20: Toxoplasmosis Therapeutics - Strategic Competitor Assessment, 2012 Figure 21: Toxoplasmosis Therapeutics - Clinical Trials by Country, 2012 Figure 22: Toxoplasmosis Therapeutics – Clinical Trials by Phase, 2012 Figure 23: Toxoplasmosis Therapeutics – Clinical Trials by Status, 2012 Figure 24: Toxoplasmosis Therapeutics – Overall Sponsors, 2012 Figure 25: Toxoplasmosis Therapeutics Market, Drivers and Barriers, 2012 Figure 26: Implications for Future Market Competition in the Toxoplasmosis Therapeutics Market, 2012 Figure 27: GlobalData Market Size Estimation Figure 28: GlobalData Market Forecasting Model
Report Price: Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Licence Type
Price
$ 3995
Site Licence
$ 7990
Enterprise Wide Licence
$ 11985
Related Reports: Posttraumatic Stress Disorder Therapeutics (PTSD) - Pipeline Assessment and Market Forecasts to 2019 Acute Spinal Cord Injury (ASCI) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Amnesia Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Melanoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Nasopharyngeal Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Waldenstrms Macroglobulinemia Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Gastrointestinal Stromal Tumors (GIST) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Retinoblastoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Ankylosing Spondylitis Therapeutics - Pipeline Assessment and Market Forecasts to 2019
You can order this report by calling on +91 - 998 7295 242 or mail us your contact details at contact@jsbmarketresearch.com About JSB Market Research:JSB market research is a leading player in the market of research report distribution. It is onestop-shop for all information related to market research for any sector of the industry. Along with providing in-depth analysis though reports, JSB market research also provides regular Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
updates of the market though newsletters. Our reports are a well-researched work of market researchers with an extensive knowledge and a good level of market experience.
To know more on Toxoplasmosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019 http://www.jsbmarketresearch.com/healthcare-medical/r-toxoplasmosistherapeutics-pipeline-assessment-and-market-forecasts-135206
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/